NEW YORK (GenomeWeb) – Drug discovery firm Immuneering is teaming with the UK-based Dementia Discovery Fund in an effort to identify new drug targets and candidates for patients with Alzheimer's disease.

The Dementia Discovery Fund, or DDF, said today that it will spend $1.3 million to use Immuneering's drug discovery platform to analyze public data sets on Alzheimer's patients. DDF and Immuneering hope to generate new molecular entities for potential treatment of the neurodegenerative disease.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The data generated by 100,000 Genomes Project is being housed on military servers due to attacks by hackers, Naked Security reports.

A new poll finds most US adults are not familiar with personalized medicine, according to HealthDay.

Vox reports that the United Nations' Convention on Biological Diversity decided against a gene drive moratorium.

In Science this week: sequencing of neuroblastomas uncovers alterations linked to prognosis, and more.